Charge-dependent binding of polymeric IgA1 to human mesangial cells in IgA nephropathy  by Leung, Joseph C.K. et al.
Kidney International, Vol. 59 (2001), pp. 277–285
Charge-dependent binding of polymeric IgA1 to human
mesangial cells in IgA nephropathy
JOSEPH C.K. LEUNG, SYDNEY C.W. TANG, MAN FAI LAM, TAK MAO CHAN, and KAR NENG LAI
Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong
Charge-dependent binding of polymeric IgA1 to human mesan- Immunoglobulin A nephropathy (IgAN), character-
gial cell in IgA nephropathy. ized by mesangial deposition of IgA of IgA1 subclass, is
Background. IgA nephropathy (IgAN) is characterized by now recognized as the most common type of glomerulo-
raised serum IgA1 and predominant mesangial IgA1 deposits nephritis worldwide. Immunoregulatory abnormalitiesof polymeric nature. The mechanism of polymeric IgA1 (pIgA1)
involving IgA1 synthesis in IgAN have been documented,deposition in the kidney mesangium is poorly understood in
and these include overproduction of IgA1 by B lympho-IgAN. It has been suggested that increased sialic acid content
and anionic charge of the pIgA1 molecules may be operational cytes in vitro [1, 2], a raised serum level of IgA, IgA-
in the IgA1 deposition in human mesangial cells (HMCs). The containing immune complexes [3, 4], and IgA of an an-
present study examined the binding of pIgA1 with different ionic nature [5, 6]. However, the pathogenesis of IgANsurface charges to HMCs. The binding characteristics of IgA1 remains obscure, since none of these abnormalities canto HMCs in the presence of polycation (poly-l-lysine) or poly-
adequately explain how IgA1 is deposited in the glomeru-anion (heparin) were also investigated.
Methods. IgA1 was purified in sera from patients with IgAN lar mesangium and how these IgA1 deposits cause glo-
and from healthy controls by jacalin affinity chromatography. merular injury.
IgA1 was further separated into pIgA1 and monomeric IgA1 The majority of serum proteins, including IgA, carry
(mIgA1) by fast protein liquid chromatography (FPLC). pIgA1 carbohydrate components. IgA1 is heavily glycosylatedor mIgA1 with different net charges on their surface were
and consists of 8% carbohydrate. The five O-linked gly-resolved by ion exchange chromatography (IEC) with a Mono
cosylation sites at the hinge region between the CH1 andQ column. The binding characteristics of pIgA1 and mIgA1 to
HMCs in the presence or absence of polycation or polyanion CH2 domains of the a chain on IgA1 are distinctive and
were examined by flow cytometry. unusual features that are not found in most of the serum
Results. In patients with IgAN, the absolute amount of proteins, including IgA2 [7]. There are at least five differ-mIgA1 and pIgA1 is significantly higher than that of healthy ent O-glycan structures at the hinge region of the a1controls (P , 0.001). There was significant increase in binding
chain in IgA1, with 64% of them being monosialylatedof pIgA1 from patients with IgAN to HMC and cell lysate.
or disialylated [8]. Because of different site occupancypIgA1 that interacted strongly with the ion exchanger also
bound more to HMCs when compared with IgA1 interacted and occurrence of a mixture of the five O-glycan types,
weakly with the ion exchanger (P , 0.001). The anionic charged an array of IgA1 consisting of a mixture of O-glycoforms
pIgA1 from patients was significantly higher than that of healthy is found. This phenomenon is called microheterogeneity
controls (P , 0.001). Preincubation with poly-l-lysine in-
of carbohydrates, which means that IgA1 could have acreased the binding of pIgA1 to HMCs. The binding of pIgA1
variety of carbohydrate structures despite the sameto HMCs was decreased by preincubation with heparin.
amino acid sequence [9]. Microheterogeneity exists inConclusions. The binding of IgA to HMCs is charge depen-
dent. Polymeric IgA with the highest net negative charge binds healthy individuals, and factors controlling the occupa-
more to HMCs. Preincubation with polyanion decreased the tion of potential O-glycosylation sites, their galactosyla-
binding of polymeric IgA to HMCs. These results suggest an tion and sialylation, remain unknown. The O-glycosyla-
important role for anionic charge in IgA1 deposition onto the tion at the hinge region of IgA1 has recently attractedkidney mesangial cells.
much attention with regard to the hepatic clearance of
IgA1 by asialoglycoprotein receptor (ASGPR). Andre,
Le Pogamp, and Chevet first reported reduced bindingKey words: anionic charge, polycation, charge dependent IgA binding,
deposits of IgA, kidney mesangial cells, glomerulonephritis, cell injury. of IgA1 to jacalin due to an unusual glycosylation of IgA1
in IgAN [10]. Other studies using carbohydrate-specificReceived for publication April 26, 2000
lectin binding assays and matrix-assisted laser desorp-and in revised form July 6, 2000
Accepted for publication July 24, 2000 tion/ionizing mass spectrometry analysis (MALDI-MS)
suggested that the abnormality is a reduction in the ter-Ó 2001 by the International Society of Nephrology
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minal galactosylation of O-linked glycans of the IgA1 by the presence of predominant granular IgA deposits,
mainly in the glomerular mesangium and occasionallymolecule [11, 12]. It was suggested that reduced terminal
galactosylation of O-linked glycans at the hinge region along the peripheral capillary basement membrane by
immunofluorescence studies, as well as mesangial elec-may modify the conformational stability of the IgA1 mol-
ecules and, consequently, the interaction with the recep- tron-dense deposits in ultrastructural examination. Sys-
temic lupus erythematosus, Henoch-Scho¨nlein purpura,tors, extracellular matrix, and the surface proteins that
may favor a reduced catabolism and clearance [13]. How- and hepatic disease were excluded by detailed clinical
history, examination, and negative laboratory testing forever, few studies have examined the sialylation of the
O-linked glycans of IgA1 in IgAN. Changes in the highly hypocomplementemia, anti-DNA antibody, or hepatitis
B virus surface antigen. No significant renal impairmentnegatively-charged sialic acid could exert a profound
effect on the binding of IgA1 molecules to mesangial was documented in these patients, and their endoge-
nous creatinine clearances were greater than 70 mL/min/cells. Contradictory results have been reported in the
sialic acid content of IgA1. Dueymes et al showed that 1.73 m2. Twenty milliliters of blood were collected from
each patient at clinical quiescence. The serum was iso-the sialic acid content was increased in IgAN [14]. Hiki
et al reported that the glycans at the hinge region of lated and frozen at 2208C until for isolation of IgA1 by
a jacalin-agarose affinity column. Serum IgA levels wereIgA1 from IgAN patients contained less N-acetylneur-
aminic acid (NeuNAc) residues attached to GalNAc [15]. determined by nephelometry.
Thirty healthy subjects (14 males and 16 females),Tomana et al also showed that there was an increased
binding of GalNAc-specific lectins after the removal of comparable in age and race with no microscopic hematu-
ria or proteinuria, were used as controls. Serum wasNeuNAc [16]. Our previous study reported a reduction
of terminal glycosylation in monomeric IgA1 (mIgA1), similarly collected from these individuals.
but not in polymeric IgA1 (pIgA1) isolated from patients
Culture of human mesangial cell culturewith IgAN [17]. Instead, an oversialylation of IgA1 was
demonstrated in pIgA1. We speculate that oversialyla- Isolation and characterization of HMCs were per-
formed as previously described [18]. Glomeruli were pre-tion will alter the overall charge of IgA1 molecules, thus
favoring their deposition onto the mesangial cell surface. pared from the cortex of human cadaveric kidney judged
to be unsuitable for transplantation or from the intactTo test this hypothesis, we purified pIgA1 fractions with
different charges and examined their binding characteris- pole of kidneys removed for circumscribed tumor. Histo-
logic examination of these kidney samples revealed notics to cultured human mesangial cells (HMCs). The
effect of altering the cell surface charge on IgA1 binding renal pathology. Glomerular cells were grown in RPMI
1640 medium supplemented with glutamine (2 mmol/L),to HMCs was investigated.
N - [2 - hydroxyethyl] - piperazine - N9 - [2 - ethanesulfonic
acid] (HEPES; 10 mmol/L), penicillin (50 U/mL), strep-
METHODS
tomycin (50 mg/mL), and 12% fetal calf serum in an
Materials atmosphere of 5% CO2/95% air. Mesangial cells have a
stellate appearance and grow in clumps. They show aRPMI 1640 and fetal bovine serum were obtained
from Life Technologies (Rockville, MD, USA). Fluores- network of intracellular fibrils of myosin, and they con-
tract in the presence of 1 nmol/L of angiotensin II. Mes-cein or peroxidase-conjugated rabbit anti-human IgA
and FITC-isotypic control antibodies used for flow cy- angial cells at the fourth to seventh passages were used.
tometry were obtained from Dako (Kyoto, Japan). Ja-
Purification and characterization of polymeric andcalin agarose was obtained from Pierce (Rockford, IL,
monomeric IgA1 by jacalin affinity chromatographyUSA). Superose Fast Protein Liquid Chromatography
and fast protein liquid chromatography(FPLC) column and Mono Q column were obtained
from Amersham Pharmacia Biotech (Uppsala, Sweden). IgA1 was purified using a jacalin-agarose affinity col-
umn, and IgA1 was fractionated at room temperature byConsumable for electrophoresis was obtained from Bio-
Rad Laboratories (Hercules, CA, USA). All other chem- the fast protein liquid chromatography (FPLC) system
(Pharmacia, Uppsala, Sweden) as described previouslyicals were obtained from Sigma (St. Louis, MO, USA).
[19]. mIgA1 and pIgA1 were separated by FPLC follow-
Patients and controls ing affinity chromatography with jacalin. The identity
of IgA after FPLC was confirmed by anti-IgA affinityThirty Chinese patients (16 males and 14 females)
with a clinical and renal immunopathologic diagnosis of chromatography and an IgA sandwich enzyme-linked
immunosorbent assay (ELISA). Two pooled fractionsprimary IgAN were studied. They had been symptomatic
for 12 months or more, with proteinuria ranging from from fractions 20 to 33 (pIgA1 fractions) and from frac-
tions 34 to 50 (mIgA1 fractions) were prepared for fur-0.4 to 2.9 g/day, and were between 19 and 45 years of
age (mean 6 SD, 28.2 6 6.3 years). IgAN was diagnosed ther analysis. pIgA1 was high molecular mass IgA with
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molecular weights between 250 and 1000 kD. mIgA1 was cein-conjugated F(ab9)2 fragment of rabbit anti-human
IgA. Background control staining was achieved by reac-low molecular mass IgA with molecular weights between
100 and 250 kD. The content of IgG in the fraction was tion with preimmune FITC-F(ab9)2. The stained cells were
analyzed using a Coulter EPICS XL analyzer (Coultermeasured by an anti-IgG ELISA. The pooled fractions
were dialyzed and concentrated to 2 mL with Centriprep Electronic, Miami, FL, USA). A minimum of 5000 fixed
cells for each sample was analyzed. Fluorescence inten-(Amicon, Beverly, MA, USA) and stored at 2708C until
use. The purity of IgA1 fractions was confirmed by so- sity was evaluated by comparing the mean fluorescence
channels. The result was expressed as mean fluorescencedium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) and ELISA [19]. The isoelectric point (pI) intensity (MFI).
was determined by isoelectric focusing (IEF) as de-
Binding assay of IgA1 subfractions to humanscribed previously [20].
mesangial cell lysate
Separation of polymeric and monomeric IgA1 Human mesangial cells were grown to log phase. The
fractions with different charges of by anion cells were then lyzed with cold lysis buffer containing
exchange chromatography 1% Triton X-100, 0.1% SDS, 5 mg/mL sodium deoxycho-
late, 0.5 mg/mL leupeptin, 1 mmol/L EDTA, 1 mg/mLOne milliliter pIgA1 or mIgA1 pooled fraction was first
dialyzed with binding buffer (20 mmol/L Tris-HCl, pH pepstatin, and 0.2 mmol/L phenylmethylsulfonyl fluoride
(PMSF). Immulon 2 microtiter plates (Dynatech, Marnes8.0) before applying onto a Mono Q HR 5/5 column.
The column was first equilibrated with 20 mL of binding la Coquette, France) were coated with 100 mL mesangial
cell lysate in 0.1 mol/L carbonate-bicarbonate buffer atbuffer, and the bound IgA was eluted with 12.5 mL of
elution buffer (a linear salt gradient from 0 to 1 mol/L a final concentration of 10 mg/mL, pH 9.6. The plates
were incubated overnight at 48C and were then washedNaCl in 20 mmol/L Tris-HCl, pH 8.0). Subfractions of
250 mL were collected throughout the elution. Fifty mi- three times with PBS-Tween. After blocking the nonspe-
cific binding sites with 3% bovine serum albumin in PBS,croliters of the eluted subfractions were stored for cell
lysate binding ELISA. The rest of subfractions eluted the plates were again washed three times with PBS-
Tween. One hundred microliters of diluted fractionswith 0.2 to 0.35 mol/L NaCl in 20 mmol/L Tris-HCl
was pooled as polymeric or mIgA1 bearing less anionic were introduced. After incubation at 378C for two hours,
the plates were washed three times with PBS-Tweencharges (pIgA P1 or mIgA P1). The subfractions eluted
with 0.35 mol/L to 0.55 mol/L NaCl in 20 mmol/L Tris- before adding 100 mL of rabbit anti-human IgA with horse-
radish peroxidase (HRP) conjugate (1:10000). After in-HCl were pooled as polymeric or mIgA1 bearing more
anionic charges (pIgA P2 or mIgA P2). The pooled sub- cubation, the plates were washed three times with PBS-
Tween, and 100 mL freshly prepared substrate solutionfractions were dialyzed and concentrated to 500 mL. IgA
concentration in the pooled subfractions was assayed by containing 0.034% (wt/vol) O-phenylenediamine pow-
der in 10 mL citrate/phosphate buffer with urea hydro-a sandwich ELISA as described previously [19]. The
pooled subfractions were then stored at 2708C until gen peroxide were added. The plates were incubated at
room temperature for a further 10 minutes before theused.
The purified subfractions from patients or controls reaction was stopped with 100 mL 2 mol/L sulfuric acid.
Finally, the reaction was terminated by addition of 50 mLused for subsequent binding studies to HMCs were ap-
propriately diluted to achieve comparable levels of IgA1. per well 1 mol/L sulfuric acid. The absorbances were
measured at 490 nm using a Microplate Reader (Labsys-This was performed in order to avoid any increased bind-
ing of IgA1 due to elevated IgA1 concentrations in puri- tem, Helsinki, Finland).
fied IgA1 subfractions.
Treatment of human mesangial cells with poly-L-lysine
or heparinBinding of IgA1 subfractions to human mesangial cells
Human mesangial cells were grown to log phase and Human mesangial cells were grown to log phase and
harvested by using 0.05% trypsin. The cells were allowedwere harvested by using 0.05% trypsin/0.02% ethylene-
diaminetetraacetic acid (EDTA) for five minutes at room to recover overnight in suspension with gentle shaking.
The trypsinized-recovered cells were adjusted to 5 3 106temperature. The cells were adjusted to 5 3 106 per
mL, and 200 mL of cell suspension were used in binding per mL, and 100 mL of cell suspension were used for the
experiments. The cells were then incubated with poly-assays. All staining was done at 48C with staining buffer
[phosphate-buffered saline (PBS) with 1% fetal bovine l-lysine or heparin at different doses for five minutes at
48C. After incubation, the cells were washed with PBS,serum and 0.1% sodium azide]. The cells were incubated
with 100 mL various subfractions of IgA1 for 30 minutes. and 10 mg of different IgA1 subfractions were added
before incubating for further 30 minutes. After incuba-After incubation, the cells were washed with staining buf-
fer and then further incubated with 100 mL of fluores- tion, the amount of IgA1 subfractions bound by the mes-
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the dimeric IgA1 from mIgA1. The pI of pIgA ranged
from 5.8 to 6.9, whereas that of mIgA was from 5.0 to
6.9. There was no significant difference in the range of
pI distribution between mIgA1 and pIgA1 isolated from
patients and control (data not shown).
Separation of polymeric and monomeric IgA with
different charges by anion exchange chromatography
Figure 3 illustrates the results of separating pIgA1 or
mIgA1 by ion exchange chromatography (IEC) using
the Mono Q column. The bound IgA1 was eluted using
gradient of increasing ionic strength with NaCl. pIgA1
was eluted between 0.32 mol/L NaCl and 0.48 mol/L
NaCl. The major peak of the eluate was at 0.36 mol/L
NaCl with a minor peak at 0.42 mol/L NaCl. mIgA1 was
Fig. 1. Separation of jacalin-purified IgA1 by size exclusion chromatog- eluted between 0.27 mol/L NaCl and 0.55 mol/L NaCl.
raphy with fast-protein liquid chromatography (FPLC). The protein
The major peak of eluate was at 0.32 mol/L NaCl withconcentration eluted from the column was express as OD 280 unit (s).
One-milliliter fractions were collected and analyzed by ELISA for the several minor peaks at 0.48 mol/L, 0.51 mol/L, and 0.54
content of IgA (d). mol/L NaCl. There was no difference in the pattern of
chromatograms between IgAN patients and controls for
pIgA1 or mIgA1 separated by the Mono Q column (data
not shown). Figure 4 shows the levels of IgA1 in differentangial cells was determined by flow cytometry as de-
subfractions eluted from the Mono Q column. The IgA1scribed previously in this article.
levels in subfractions pIgA P1, pIgA P2, and mIgA P1
were significantly higher in IgAN patients than controlsStatistics
(P , 0.001). The amount of pIgA P2 (that were more
The results are expressed as mean 6 SD. The Student’s
anionic in nature) represented 2.0 to 2.5% of total puri-
unpaired t test was used to compare values from both
fied IgA1 from IgAN patients or healthy controls.patient and control groups.
Binding of IgA1 subfractions to human mesangial cells
and mesangial cell lysateRESULTS
Figure 5 depicts the binding of IgA1 subfractions sepa-Purification of monomeric and polymeric IgA1
rated by the Mono Q column to HMC. There was no
A typical chromatogram of IgA1 separated by FPLC significant difference between binding to HMC in mIgA1
is shown in Figure 1. Pooled fractions 20 to 33 were (including mIgA P1 and mIgA P2) from patients or con-
pIgA1 with molecular weights between 250 and 1000 kD. trols. In contrast, pIgA1 with more anionic surface charge
Pooled fractions 33 to 40 were mIgA1 with molecular (pIgA P2) exhibited a higher binding to HMCs among
weights between 120 and 250 kD. No IgG or IgM was the IgA1 subfractions (MFI 5 2.32 6 0.21 vs. MFI of pIgA
detected in the mIgA1 fractions, and IgG represented P1 5 1.32 6 0.13, P , 0.001). Moreover, the binding of
0.1% of total protein in pIgA1 fractions, as measured pIgA P1 and pIgA P2 subfractions from IgAN patients
by ELISA. The serum IgA level in patients with IgAN to HMC was significantly higher than the corresponding
(3.02 6 1.54 g/L) was significantly higher than that of values from controls (P , 0.001).
healthy controls (1.84 6 0.82 g/L, P , 0.001). Studies of Figure 6 illustrates a typical binding pattern of IgA1
IgA1 in FPLC fractions by IgA ELISA showed that subfractions from a patient with IgAN to HMC lysate.
mIgA1 amounted to 92% of total IgA1 from either The binding of pIgA1 subfractions to mesangial cell ly-
healthy controls or patients (data not shown). Similarly, sate was much higher than that of mIgA1. The more
pIgA1 represented 8% of total IgA1 from either group anionic subfractions of pIgA1 exhibited the highest bind-
of subjects. The ratio of monomeric to pIgA1 did not ing to HMC lysate. A similar pattern of binding was also
differ between patients and controls. Figure 2 depicts observed in subfractions isolated from normal controls
results of SDS-PAGE and IEF analysis of the pooled (data not shown).
fractions of polymeric and mIgA1. mIgA1 fractions con-
Binding of IgA1 subfractions to human mesangial cellssisted of mainly mIgA1 with a size of 160 kD, and there
after preincubation with polyionswas no pIgA1 copurified in these fractions. pIgA1 frac-
tions contained mainly dimeric IgA1 with small mIgA1 Figure 7 illustrates the effect of preincubating HMC
with poly-l-lysine or heparin on the binding of IgA1contamination because of the incomplete separation of
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Fig. 2. Isoelectric focusing (IEF; upper) and
sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE; lower) analysis
of purified pooled pIgA1 and mIgA1 fractions.
subfractions. Preincubation with poly-l-lysine (0.625 to lated to bear pathological implication in IgAN [21, 22].
Deficiency of terminal galactose in O-glycans at the20 mg/mL) significantly increased the binding of pIgA, or
hinge region may have a profound effect on the recogni-mIgA1 to HMCs in a dose-dependent manner. Similarly,
tion of IgA1 by ASGPR and, hence, its catabolism. Oligo-preincubation with heparin (0.625 to 20 U/mL) signifi-
saccharides at the hinge region carry negatively chargedcantly decreased the binding of IgA1 to HMCs in a dose-
sialic acid that is large and bulky compared with thedependent manner. Figure 8 summarizes the effect of
protein backbone. Any change in the carbohydrate moie-preincubating the HMCs with polyanion or polycation
ties affects the tertiary structure as well as the electro-on the binding of different IgA1 subfractions from both
static charges that are pivotal in the interaction withgroups of subjects. Preincubation with 5 mg/mL poly-l-
and recognition by other receptors such as ASGPR andlysine increased the binding of pIgA1 or mIgA1 to HMCs
FcaR1 [13, 22]. Earlier studies revealed a reduced termi-in both patients and controls (P , 0.001). Preincubated
nal galactosylation of serum IgA1 in IgAN [11, 22]. How-HMCs with heparin (5 U/mL) significantly reduced the
ever, these findings failed to provide a pathogeneticbinding of pIgA1 or mIgA1 to HMCs from patients and
mechanism in IgAN, as over 85% of serum IgA1 arecontrol (P , 0.001). In all experimental conditions, the
monomers, whereas mesangial IgA1 deposits are mainlybinding of IgA1 from patients with IgAN was significantly
polymeric and anionic in nature. We have shown thathigher than that of controls (P , 0.001).
pIgA from patients with IgAN exhibited an increased
binding to HMCs [18]. Recently, we found that the an-
DISCUSSION ionic nature of pIgA from patients with IgAN is due, at
Serum IgA consists of an assortment of glycoforms with least partly, to oversialylation of the O-glycans at the
different O-glycosylation pattern. Structural changes at hinge region [17]. Oversialylation of pIgA has two poten-
tial implications on the pathogenesis of IgAN. First, thethe hinge region of the IgA1 molecule have been specu-
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Fig. 5. Binding of pooled Mono Q-separated IgA1 subfractions to cul-
tured human mesangial cells (HMCs). Results were expressed as mean
fluorescence intensity (MFI). pIgA1 subfractions (pIgA P1 and pIgA
P2) bound more than mIgA1 subfractions to HMC. The binding for
subfractions pIgA P1 and pIgA P2 were significantly higher in patients
(j) than controls (h); **P , 0.001.
masking effect of sialic acid may hinder the binding of
pIgA to ASGPR that is specific for terminal galactose
residues. Hence, these large macromolecular IgA notFig. 3. Separation of polymeric pIgA1 (pIgA1; upper chromatogram)
and monomeric IgA1 (mIgA1; lower chromatogram) by anion exchange effectively removed from the circulation by the ASGPR
chromatography with a Mono Q column. The fractions eluted with less in the reticulo-endothelial system will be filtered andthan 0.4 mol/L NaCl were pooled as pIgA P1 or mIgA P1, and those
deposited in kidneys. In fact, it has been reported thatfractions eluted with more than 0.4 mol/L NaCl were pooled as pIgA
P2 and mIgA P2. increased sialylation causes elongation of glycans in IgM
and reduces the clearance by the ASGPR [23]. Second,
oversialylation renders pIgA from patients with IgAN
more anionic, and this enhances the mesangial deposi-
tion of IgA immune complexes. These assumptions
prompt us to examine whether the serum IgA1s from
patients with IgAN are bearing different levels of anionic
charges and, if so, whether they bind differently to HMC.
Herein, we have developed a novel scheme of purifica-
tion to separate anionic-charged pIgA1 from sera of hu-
man subjects. We found that the level of anionic-charged
pIgA1 (that is, pIgA1 P2) was increased in patients with
IgAN, yet the level of anionic-charged mIgA1 (that is,
mIgA1 P2) remained unaltered. There was no change in
the distribution of isoelectric point (pI) of polymeric IgA
isolated by FPLC from patients or controls. This may
be due to the fact that the increased amount of anionic-
charged pIgA1 (that is, pIgA1 P2) was small as compared
with the total polymeric IgA level, and the difference
could not be reflected by the IEF analysis. Increased
proportion of anionic IgA1 and reduced cationic portion
had been reported in serum of patients with IgAN
Fig. 4. IgA1 content of purified pooled, Mono Q-separated IgA1 sub- [20, 24]. In this study, we found that the increased anionic
fractions. The IgA1 level for subfractions pIgA P1, pIgA P2, and mIgA
IgA1 was predominantly polymeric, and these anionicP1 were significantly higher in patients (j) than controls (h); **P ,
0.001. pIgA1s had the highest affinity to mesangial cells despite
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Fig. 6. Binding of pIgA1 (d) and mIgA1 (m) from patients with IgAN Fig. 7. Binding of pIgA1 (A) and mIgA1 (B) from patients with IgANto cell lysates prepared from cultured HMCs. Upper chromatogram (j) or control (d) to cultured HMCs after preincubation with increasing
(A) shows the elution pattern from Mono Q column. Lower figure (B) dose of poly-L-lysine (mg/mL; solid line) or heparin (U/mL; dotted line).
represents the result of ELISA assay.
that they only represented a very small percentage of whether an individual IgA1 molecule is sialylated cannot
total purified IgA1. This is consistent with the previous be simply predicted from the percentage of different gly-
finding of mesangial IgA1 deposits in renal biopsies by can components. The exact site occupancy of O-glycan
Monterio et al [25]. They found that 64% of the eluted is an important factor in determining the physiochemical
IgA from the biopsy in IgAN was polymeric and anionic properties of the IgA1 molecule. Besides electrostatic
in nature. Recently, O-glycans in IgA1 from patients with interaction, it has been proposed that the binding of
IgAN had been analyzed by fluorophore-assisted carbo- human IgA1 to HMCs may be mediated through specific
hydrate electrophoresis. Allen et al demonstrated a sig- IgA receptors such as FcaR (CD89), ASGPR, and poly-
nificant increase in the percentage of O-glycans with meric immunoglobulin receptors [27–29]. However, the
single N-acetyl galactosamine (GalNAc) units, but there
possibility of these receptors being actively involved inwas no difference in the percentage of sialylated glycans
mediating IgA deposition is not supported by latest stud-[26]. Their observation does not necessarily contradict
ies documenting their absence in mesangial cells [30–32].our finding for which pIgA1 are more anionic. It is possi-
Lately, novel receptor for IgA had been reported inble that both undergalactosylated and oversialylated
mesangial cells, which is distinct from the myeloid FcaRIgA1 molecules may be presented in the total bulk of
CD89 [33]. This novel receptor binds pIgA with highIgA1 purified from the same individual because of the
affinity. It is possible that both receptor-mediated bind-variable occupancy of the five potential O-glycosylation
sites at the hinge region. It should be pointed out that ing and charge-dependent binding operate together to
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synthesis and increased cytosolic-free calcium level [37].
It was suggested that neutralization of anionic sites on
mesangial cells might affect the inflammatory response.
With chronic inflammatory process, polyanionic sites on
the mesangial cells could be altered by enzymatic attack,
and degradation of anionic moieties occurred because
of cationic enzymes released from activated platelets or
leukocytes [38]. These enzymes include acid or neutral
proteinase, endoglycosidase, and heparinase. Moreover,
endogenous cationic proteins such as platelet factor 4
that released from activated platelets or leukocyte are
capable of neutralizing glomerular polyanionic sites [39].
Neutralization or damage of glomerular polyanionic sites
may compromise the electrostatic barrier to circulating
IgA1, thus leading to glomerular deposition. The thera-
peutic potential of polyanions for treating of IgAN
awaits further exploration. Heparin is known to have
anti-inflammatory properties, including complement in-
activation and suppression of leukocyte functions [40].
Heparin inhibits migration and mitogenesis of cultured
mesangial cells [41]. Recently, the anti-apoptotic poten-
tial of heparin was demonstrated in a variety of kidney
cells, including HMCs [42]. Based on our present find-
Fig. 8. Binding of pooled pIgA1 (A) or mIgA1 (B) in patients (j) or ings, further investigation should be taken to determinecontrol (h) to cultured HMCs after preincubating the cells with 5
whether heparin could ameliorate the progression ofmg/mL poly-L-lysine or 5 U/mL heparin. Results were expressed as
mean fluorescence intensity (MFI). Poly-l-lysine significantly increased IgAN by abrogating further mesangial IgA1 deposition.
the binding of pIgA1 or mIgA1 in patients with IgAN, whereas heparin In conclusion, increased levels of anionic-chargedsignificantly decreased the binding (P , 0.001 in both cases). In all
pIgA1 were found in IgAN. Although anionic-chargedexperimental conditions, the binding of IgA1 from patients with IgAN
was significantly higher than that of controls (P , 0.001). pIgA1 only represents a small fraction of total serum
IgA, in vitro studies show that its binding to mesangial
cells is the highest among all fractions of serum IgA1.
Our findings suggest that the anionic property of IgAmediate pIgA binding to mesangial cells. Further investi-
plays a crucial role in mesangial IgA1 deposition in pa-gation is warranted.
tients with IgAN.To elucidate further the role of electrostatic charge
on mesangial deposition of IgA, we deliberately altered
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